Dasatinib - 302962-49-8

Dasatinib

Catalog Number: EVT-333705
CAS Number: 302962-49-8
Molecular Formula: C22H26ClN7O2S
Molecular Weight: 488 g/mol
The product is for non-human research only. Not for therapeutic or veterinary use.
Price:

Product Introduction

Description
Dasatinib is a small molecule drug that belongs to the class of tyrosine kinase inhibitors. It was first approved by the FDA in 2006 for the treatment of chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). Since then, it has been extensively studied for its potential therapeutic applications in various other diseases, including solid tumors, autoimmune disorders, and viral infections.
Applications in Various Fields
Dasatinib has several applications in medical research, including its role in drug development, clinical trials, and findings, benefits, and potential side effects. In environmental research, dasatinib's effects on ecosystems, role in pollution management, and sustainability and environmental impact are also important considerations. In industrial research, dasatinib's use in manufacturing processes, improving product quality and efficiency, and health and safety considerations are also important.

Properties

CAS Number

302962-49-8

Product Name

Dasatinib

IUPAC Name

N-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)piperazin-1-yl]-2-methylpyrimidin-4-yl]amino]-1,3-thiazole-5-carboxamide

Molecular Formula

C22H26ClN7O2S

Molecular Weight

488 g/mol

InChI

InChI=1S/C22H26ClN7O2S/c1-14-4-3-5-16(23)20(14)28-21(32)17-13-24-22(33-17)27-18-12-19(26-15(2)25-18)30-8-6-29(7-9-30)10-11-31/h3-5,12-13,31H,6-11H2,1-2H3,(H,28,32)(H,24,25,26,27)

InChI Key

ZBNZXTGUTAYRHI-UHFFFAOYSA-N

SMILES

CC1=C(C(=CC=C1)Cl)NC(=O)C2=CN=C(S2)NC3=CC(=NC(=N3)C)N4CCN(CC4)CCO

Solubility

1.28e-02 g/L

Synonyms

(18F)-N-(2-chloro-6-methylphenyl)-2-(6-(4-(2-hydroxyethyl)piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide
354825, BMS
BMS 354825
BMS-354825
BMS354825
dasatinib
N-(2-chloro-6-methylphenyl)-2-(6-(4-(2-hydroxyethyl)piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide
Sprycel

Canonical SMILES

CC1=C(C(=CC=C1)Cl)NC(=O)C2=CN=C(S2)NC3=CC(=NC(=N3)C)N4CCN(CC4)CCO
Method of Synthesis or Extraction
Dasatinib is synthesized through a multi-step process that involves the condensation of 2-chloro-N-(2-oxo-1-phenyl-3,4-dihydroquinazolin-6-yl) acetamide with 4-(dimethylamino) butyric acid. The reaction is carried out in the presence of a base and a coupling agent, such as N,N'-dicyclohexylcarbodiimide (DCC) or N,N'-diisopropylcarbodiimide (DIC). The resulting product is then purified by column chromatography and recrystallization.
The efficiency and yield of the synthesis process depend on several factors, such as the quality of the starting materials, the reaction conditions, and the purification methods. Typically, the yield of dasatinib synthesis ranges from 30% to 50%. However, several modifications to the synthesis process have been proposed to improve the yield and reduce the cost of production.
Environmental and safety considerations are also important factors to consider in the synthesis of dasatinib. The use of hazardous chemicals, such as DCC and DIC, can pose a risk to the environment and human health. Therefore, alternative coupling agents and solvents that are less toxic and more environmentally friendly have been investigated.
Chemical Structure and Biological Activity
Dasatinib is a small molecule with a molecular weight of 488.01 g/mol. Its chemical structure consists of a pyrimidine ring, a quinazoline ring, and a thiazole ring, which are connected by a linker chain. The drug binds to the ATP-binding site of tyrosine kinases, inhibiting their activity and preventing the phosphorylation of downstream signaling molecules.
The biological activity of dasatinib is primarily attributed to its inhibition of the BCR-ABL kinase, which is a fusion protein that is commonly found in Dasatinib and Ph+ ALL. In addition, dasatinib also inhibits other tyrosine kinases, such as SRC family kinases, c-KIT, and PDGFR, which are involved in various cellular processes, including cell proliferation, differentiation, and survival.
The potency of dasatinib varies depending on the target kinase and the cellular context. In vitro studies have shown that dasatinib has nanomolar to low micromolar IC50 values against BCR-ABL and SRC family kinases. In vivo studies have also demonstrated the efficacy of dasatinib in animal models of Dasatinib and solid tumors.
Biological Effects
The biological effects of dasatinib on cell function and signal transduction are complex and depend on the specific target kinase and the cellular context. In general, dasatinib inhibits the phosphorylation of downstream signaling molecules, leading to the inhibition of cell proliferation, survival, and migration.
The potential therapeutic effects of dasatinib have been extensively studied in various diseases, including Dasatinib, Ph+ ALL, solid tumors, autoimmune disorders, and viral infections. In clinical trials, dasatinib has shown promising results in the treatment of Dasatinib and Ph+ ALL, with high rates of complete cytogenetic response and major molecular response.
However, dasatinib also has potential toxic effects, such as myelosuppression, fluid retention, and cardiovascular toxicity. These side effects can limit the use of dasatinib in certain patient populations and require careful monitoring and management.
Future Perspectives and Challenges
Current limitations in the use and study of dasatinib include its potential toxic effects, limited efficacy in certain patient populations, and the development of resistance. Possible solutions and improvements include the development of more selective and potent tyrosine kinase inhibitors, combination therapies, and personalized medicine approaches.
Future trends and prospects in the application of dasatinib in scientific research include the exploration of its potential therapeutic applications in other diseases, such as autoimmune disorders and viral infections, and the development of novel drug delivery systems.

Product FAQ

Q1: How Can I Obtain a Quote for a Product I'm Interested In?
  • To receive a quotation, send us an inquiry about the desired product.
  • The quote will cover pack size options, pricing, and availability details.
  • If applicable, estimated lead times for custom synthesis or sourcing will be provided.
  • Quotations are valid for 30 days, unless specified otherwise.
Q2: What Are the Payment Terms for Ordering Products?
  • New customers generally require full prepayment.
  • NET 30 payment terms can be arranged for customers with established credit.
  • Contact our customer service to set up a credit account for NET 30 terms.
  • We accept purchase orders (POs) from universities, research institutions, and government agencies.
Q3: Which Payment Methods Are Accepted?
  • Preferred methods include bank transfers (ACH/wire) and credit cards.
  • Request a proforma invoice for bank transfer details.
  • For credit card payments, ask sales representatives for a secure payment link.
  • Checks aren't accepted as prepayment, but they can be used for post-payment on NET 30 orders.
Q4: How Do I Place and Confirm an Order?
  • Orders are confirmed upon receiving official order requests.
  • Provide full prepayment or submit purchase orders for credit account customers.
  • Send purchase orders to sales@EVITACHEM.com.
  • A confirmation email with estimated shipping date follows processing.
Q5: What's the Shipping and Delivery Process Like?
  • Our standard shipping partner is FedEx (Standard Overnight, 2Day, FedEx International Priority), unless otherwise agreed.
  • You can use your FedEx account; specify this on the purchase order or inform customer service.
  • Customers are responsible for customs duties and taxes on international shipments.
Q6: How Can I Get Assistance During the Ordering Process?
  • Reach out to our customer service representatives at sales@EVITACHEM.com.
  • For ongoing order updates or questions, continue using the same email.
  • Remember, we're here to help! Feel free to contact us for any queries or further assistance.

Quick Inquiry

 Note: Kindly utilize formal channels such as professional, corporate, academic emails, etc., for inquiries. The use of personal email for inquiries is not advised.